Varices

FibroScan® by Echosens Recognized in AASLD Practice Guidance on Managing Portal Hypertension and Varices in Cirrhosis

Retrieved on: 
Vendredi, novembre 10, 2023
Elastography, Lipinski's rule of five, Dominique, Literature, AASLD, HVPG, Cirrhosis, Liver disease, Mortality, Patient, SSM, Varices, Prognosis, Diagnosis, Decompensation, Chronic liver disease, Platelet, Medical imaging

PARIS and WESTBOROUGH, Mass., Nov. 10, 2023 /PRNewswire/ -- The American Association for the Study of Liver Disease (AASLD) has released new guidance advocating noninvasive tests like FibroScan® for the management of advanced liver disease, including assessment of clinically significant portal hypertension and varices in cirrhosis. This evidence-based approach could impact health outcomes for the majority of asymptomatic patients with this condition.

Key Points: 
  • "Managing portal hypertension in cirrhotic patients is a daily challenge for healthcare professionals," said Jon Gingrich, CEO of Echosens North America .
  • "Given the high mortality rates associated with these conditions, there's an urgent need for effective treatments and early diagnosis.
  • The latest guidance underscores the promise of noninvasive methods for monitoring advanced liver disease patients."
  • This new guidance encapsulates optimal practices for identifying and managing portal hypertension and varices in chronic liver disease.

Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress™ 2022

Retrieved on: 
Mardi, juin 21, 2022
Cirrhosis, Esophageal varices, Animal, Liver disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Cedars-Sinai Medical Center, Non-alcoholic fatty liver disease, Machine, Disease, Fatty liver disease, CA, Therapy, GLOBE, European Association for the Study of the Liver, Division, Heart, Chronic liver disease, Inflammation, Intelligence, USAN, Lung, NASDAQ, Liver transplantation, Bleeding, Fibrosis, Digestive, Varices, Kidney, Artificial intelligence, Efficacy, Galectin, Liver failure, Algorithm, Cancer, Natural history, Patient, Immunotherapy, Risk, Association, EASL, Obesity, GALT, Company, International Studies of Infarct Survival, Lists of diseases, Institute of Liver and Biliary Sciences, Safety, NASH, Head, Food, Machine learning, Medical imaging, Pharmaceutical industry, Liver

Dr Pol Boudes, Chief Medical Officer of Galectin Therapeutics commented: Galectin Therapeutics has accumulated significant clinical development expertise in liver cirrhosis and the management of portal hypertension, which represents one of the most significant clinical complications of the disease.

Key Points: 
  • Dr Pol Boudes, Chief Medical Officer of Galectin Therapeutics commented: Galectin Therapeutics has accumulated significant clinical development expertise in liver cirrhosis and the management of portal hypertension, which represents one of the most significant clinical complications of the disease.
  • Over time, patients with NASH can develop excessive fibrosis, or scarring of the liver, and ultimately liver cirrhosis.
  • Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.
  • Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics galectin-3 inhibitor GR-MD-02.

Esophageal Varices Market - Global Clinical Trials Review, H2, 2021 - ResearchAndMarkets.com

Retrieved on: 
Vendredi, octobre 8, 2021
Pharmaceutical, Health, Clinical Trials, Other Health, Decision-making, Trial, E7 (countries), Varices, Esophageal varices, Clinical trial, G7, E7, Dietary supplement, Pharmaceutical industry

The "Esophageal Varices - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Esophageal Varices - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Esophageal Varices - Global Clinical Trials Review, H2, 2021" provides an overview of Esophageal Varices Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Esophageal Varices.
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    the report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    the report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Clinical Trials by G7 Countries: Proportion of Esophageal Varices to Gastrointestinal Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Esophageal Varices to Gastrointestinal Clinical Trials

Galectin Therapeutics to Present at 4th Global NASH Congress

Retrieved on: 
Mardi, avril 27, 2021
Medical specialties, Lectins, Branches of biology, Varices, Cirrhosis, Galectin, Esophageal varices

b'NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.\nOn Thursday, April 29th, Dr. Boudes will review Galectin Therapeutics\xe2\x80\x99 scientific and clinical activities in NASH cirrhosis, followed by a Q&A session.

Key Points: 
  • b'NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes, M.D., Chief Medical Officer , will present the belapectin program at the 4th Global NASH Congress taking place virtually on April 28 and 29, 2021.\nOn Thursday, April 29th, Dr. Boudes will review Galectin Therapeutics\xe2\x80\x99 scientific and clinical activities in NASH cirrhosis, followed by a Q&A session.
  • Gal-3, a glycan binding protein, orchestrates liver inflammation and fibrosis in NASH cirrhosis.
  • Galectin is conducting a seamless, adaptive, double-blind, randomized, placebo controlled phase 2b/3 global study in patients with portal hypertension due to NASH cirrhosis who have not yet developed varices.
  • The primary outcome is the development of esophageal varices at 18 months.\nThe annual Global NASH Congress, usually held in London, will be taking place virtually on April 28 and 29, 2021.

Echosens Introduces FibroScan 630 Expert: Adds New Spleen Stiffness Measurement (SSM by VCTE™) for Risk Stratification of Patients with Advanced Chronic Liver Disease

Retrieved on: 
Lundi, novembre 9, 2020
Technology, Medical devices, Infectious diseases, Hospitals, Biotechnology, Radiology, Managed care, Health, Data management, Medical specialties, Clinical medicine, Hepatitis, Elastography, Medical imaging, Cirrhosis, Non-alcoholic fatty liver disease, Steatohepatitis, Esophageal varices, Liver, Varices, Alcoholic liver disease

Echosens , a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.

Key Points: 
  • Echosens , a high-technology company offering the FibroScan family of products, announces the launch of FibroScan 630 Expert in the United States, a comprehensive non-invasive solution for advanced liver disease management.
  • This innovative tool is designed to expand clinical capabilities in liver health assessment with the addition of spleen stiffness measurement.
  • Given the significant increase in potential cases of liver cirrhosis due to non-alcoholic steatohepatitis (NASH) and alcoholic liver disease, there is a critical need for a non-invasive evaluation tool like FibroScan 630 Expert.
  • In cirrhotic patients, spleen stiffness may correlate better with Hepatic Venous Pressure Gradient (HVPG) and presence of high-risk esophageal varices than liver stiffness.

Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis

Retrieved on: 
Lundi, novembre 11, 2019
Medical specialties, Medicine, Hepatitis, RTT, Lectins, Non-alcoholic fatty liver disease, Steatohepatitis, Cirrhosis, Siemens Healthineers, Varices, Galectin

NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.

Key Points: 
  • NORCROSS, Ga., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Today, Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced a collaboration agreement with Siemens Healthineers, a global leader in medical technology, in nonalcoholic steatohepatitis (NASH) and liver fibrosis.
  • This collaboration allows Siemens Healthineers to use Galectins Phase 2 NASH-CX clinical trial to support regulatory filings of the ADVIA Centaur Enhanced Liver Fibrosis (ELF) test.
  • This agreement will also provide Siemens Healthineers with access to future clinical and ADVIA Centaur ELF test data from Galectin Therapeutics planned Phase 3 NASH-RX clinical trial of belapectin (GR-MD-02) in the treatment of NASH liver cirrhosis without esophageal varices.
  • Siemens Healthineers was granted a Breakthrough Device designation for the ADVIA Centaur ELF test by the U.S. Food and Drug Administration (FDA) in 2018.